Sermorelin injection sites: Frequently asked questions

Repeated injection at the same site within 48–72 hours causes localized tissue inflammation and fibrosis that impair subsequent absorption. Maintain minimum 1-inch spacing between injection points within the same anatomical region, or alternate between abdomen and thigh if daily administration is required. Injection site rotation prevents lipohypertrophy (fatty tissue buildup) that reduces peptide bioavailability by 15–25% in affected areas.

Intramuscular sermorelin administration produces higher peak plasma concentrations (30–40% increase) and shorter duration compared to subcutaneous dosing due to greater muscle tissue vascularity. If research protocol requires subcutaneous kinetics, the dose must be excluded from pharmacokinetic analysis. Prevent recurrence by reducing needle insertion depth to 6mm maximum and ensuring adequate subcutaneous tissue pinch before injection.

Discard the vial immediately. Do not attempt filtration or clarification. Particulate matter indicates peptide aggregation, microbial contamination, or glass particulates from vial breakage. Administering contaminated solution introduces foreign protein aggregates or endotoxins that trigger immune responses and invalidate research data. Sermorelin should reconstitute to a clear, colorless solution within 60 seconds of adding bacteriostatic water.

Patients with low body fat (<12% for men, <20% for women) may lack sufficient abdominal adipose tissue for comfortable subcutaneous injection. In this case, expand your rotation to include the outer thigh (vastus lateralis region, mid-thigh level) as a fifth and sixth zone. Thigh injections produce slightly lower peak plasma concentrations but remain clinically effective. Alternatively, the back of the upper arm (triceps region) can serve as additional rotation zones, though this site requires assistance or flexibility to self-administer. Never inject into areas with <1 cm of pinchable subcutaneous fat. Insufficient tissue depth risks intramuscular injection, which alters absorption kinetics unpredictably.

Stop injecting into that quadrant immediately and avoid the area entirely for 12–16 weeks. The lump represents established lipohypertrophy. Continued injection into or near that tissue will worsen the nodule and further reduce absorption. Shift your rotation to the three remaining quadrants, maintaining one-inch spacing within each. Most lipohypertrophic nodules resolve spontaneously over 3–6 months once the mechanical stimulus is removed, though larger nodules (>1 cm diameter) may persist longer or require manual massage to break up fibrous tissue.

Do not guess. Injecting into a site used within the past 72 hours significantly increases lipohypertrophy risk. If you cannot definitively recall your last injection point, choose a site in a different anatomical quadrant entirely. Err toward over-rotation rather than under-rotation. Going forward, implement a tracking system: photograph your abdomen after each injection with a small adhesive dot marking the site, or use a written log with date, time, and quadrant recorded. Tracking eliminates this problem entirely.